2020 Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs
The 2020 Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline report presents a comprehensive overview of the research and development of Cognitive Impairment Associated With Schizophrenia (CIAS) drug candidates. It presents drugs in development that could potentially reach the market in the next 5 to 10 years: Eight drugs in pre-clinical phase, five drugs in phase 1 and nine drugs in Phase 2
As of February 2020, the Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline remains robust with 22 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Cognitive Impairment Associated With Schizophrenia (CIAS) treatment. Diverse types of targeted therapies are being explored through clinical trials including alpha 7 nicotinic acetylcholine receptor agonist; AMPA receptor modulators; D amino acid oxidase inhibitor; Dopamine D1 receptor positive allosteric modulator; estrogen receptor beta agonist; GABA A alpha 5 receptor modulators; glycine transporter 1 inhibitor; GPR139 agonist; Histamine H3 Inverse Agonist; Kv3 voltage-gated potassium channel; metabotropic glutamate receptor 5 (mGluR5); Muscarinic acetylcholine M4 receptor; NMDA receptor agonist; prolyl oligopeptidase inhibitor; Serotonin 4 receptor agonists.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Cognitive Impairment Associated With Schizophrenia (CIAS) drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
PUBLISHER EXPERTISE
VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
SCOPE:
Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline drugs profiled in the report include- AVL-3288, ASP4345, ASP5736, VU-0467154, AUT 00206, BIIB104, BI 425809, BMS-955829, CAD-8688, erteberel, LSN2814617, basmisanil, Cognition disorder therapeutics, IPR-19, PF-03463275, SKL20540, SP-14040, SUVN-D4010, SUVN-G3031, TAK-041, TAK-831, VQW-765
As of February 2020, the Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline remains robust with 22 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Cognitive Impairment Associated With Schizophrenia (CIAS) treatment. Diverse types of targeted therapies are being explored through clinical trials including alpha 7 nicotinic acetylcholine receptor agonist; AMPA receptor modulators; D amino acid oxidase inhibitor; Dopamine D1 receptor positive allosteric modulator; estrogen receptor beta agonist; GABA A alpha 5 receptor modulators; glycine transporter 1 inhibitor; GPR139 agonist; Histamine H3 Inverse Agonist; Kv3 voltage-gated potassium channel; metabotropic glutamate receptor 5 (mGluR5); Muscarinic acetylcholine M4 receptor; NMDA receptor agonist; prolyl oligopeptidase inhibitor; Serotonin 4 receptor agonists.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Cognitive Impairment Associated With Schizophrenia (CIAS) drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
PUBLISHER EXPERTISE
VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
SCOPE:
- The report scope comprises of both pre-clinical phase and clinical phase development drugs for Cognitive Impairment Associated With Schizophrenia (CIAS) development
- Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline compounds and molecules under study by both large scale and small companies are included in the report
- Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline across different phases including discovery, research, and pre-clinical stage, phase 1, phase 2, phase 3 and pre-registration phases are covered
- Drug profile comprising of current development status, regulatory progress, companies, sponsors, mechanism of action, route of administration, molecule, and discovery details are covered
- Further, orphan drug status, fast track designation, different grants awarded and special status for Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline candidates included
- Business overview and snapshot of all companies involved in Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline are included
- Latest market and pipeline developments are provided in the report
Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline drugs profiled in the report include- AVL-3288, ASP4345, ASP5736, VU-0467154, AUT 00206, BIIB104, BI 425809, BMS-955829, CAD-8688, erteberel, LSN2814617, basmisanil, Cognition disorder therapeutics, IPR-19, PF-03463275, SKL20540, SP-14040, SUVN-D4010, SUVN-G3031, TAK-041, TAK-831, VQW-765
1. TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2. EXECUTIVE SUMMARY
2.1 Report Scope and Research Methodology
2.2 Introduction to Cognitive Impairment Associated With Schizophrenia (CIAS) Condition
2.3 Cognitive Impairment Associated With Schizophrenia (CIAS) Pipeline Snapshot, 2020
2.4 Companies investing in Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline therapeutics
2.5 Phase wise Cognitive Impairment Associated With Schizophrenia (CIAS) Pipeline Candidates
2.6 Most Researched Mechanism of Action of Cognitive Impairment Associated With Schizophrenia (CIAS) Pipeline Products
2.7 Route of Administration of Cognitive Impairment Associated With Schizophrenia (CIAS) Pipeline Drugs
3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT
3.1 Anvyl LLC Overview, Contacts and ASD Pipeline Drugs
3.2 Astellas Pharma Inc Overview, Contacts and ASD Pipeline Drugs
3.3 AstraZeneca Plc Overview, Contacts and ASD Pipeline Drugs
3.4 Autifony Therapeutics Ltd Overview, Contacts and ASD Pipeline Drugs
3.5 Biogen Inc Overview, Contacts and ASD Pipeline Drugs
3.6 Boehringer Ingelheim International GmbH Overview, Contacts and ASD Pipeline Drugs
3.7 Bristol-Myers Squibb Co Overview, Contacts and ASD Pipeline Drugs
3.8 Cadent Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.9 Chugai Pharmaceutical Co Ltd Overview, Contacts and ASD Pipeline Drugs
3.10 Eli Lilly and Co Overview, Contacts and ASD Pipeline Drugs
3.11 INVENT Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
3.12 Iproteos SL Overview, Contacts and ASD Pipeline Drugs
3.13 Pfizer Inc Overview, Contacts and ASD Pipeline Drugs
3.14 SK Biopharmaceuticals Co Ltd Overview, Contacts and ASD Pipeline Drugs
3.15 Spherium Biomed SL Overview, Contacts and ASD Pipeline Drugs
3.16 Suven Life Sciences Ltd Overview, Contacts and ASD Pipeline Drugs
3.17 Takeda Pharmaceutical Co Ltd Overview, Contacts and ASD Pipeline Drugs
3.18 Vanda Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
4. ACTIVE PIPELINE DRUG DETAILS, 2020
4.1 AVL-3288 Drug Details
4.1.1 AVL-3288 Current Status
4.1.2 AVL-3288 Drug Overview
4.1.3 AVL-3288 Mechanism of Action
4.1.4 AVL-3288 Licensing/Collaboration Companies
4.1.5 AVL-3288 Clinical Trials
4.2 ASP4345 Drug Details
4.2.1 ASP4345 Current Status
4.2.2 ASP4345 Drug Overview
4.2.3 ASP4345 Mechanism of Action
4.2.4 ASP4345 Licensing/Collaboration Companies
4.2.5 ASP4345 Clinical Trials
4.3 ASP5736 Drug Details
4.3.1 ASP5736 Current Status
4.3.2 ASP5736 Drug Overview
4.3.3 ASP5736 Mechanism of Action
4.3.4 ASP5736 Licensing/Collaboration Companies
4.3.5 ASP5736 Clinical Trials
4.4 VU-0467154 Drug Details
4.4.1 VU-0467154 Current Status
4.4.2 VU-0467154 Drug Overview
4.4.3 VU-0467154 Mechanism of Action
4.4.4 VU-0467154 Licensing/Collaboration Companies
4.4.5 VU-0467154 Clinical Trials
4.5 AUT 00206 Drug Details
4.5.1 AUT 00206 Current Status
4.5.2 AUT 00206 Drug Overview
4.5.3 AUT 00206 Mechanism of Action
4.5.4 AUT 00206 Licensing/Collaboration Companies
4.5.5 AUT 00206 Clinical Trials
4.6 BIIB104 Drug Details
4.6.1 BIIB104 Current Status
4.6.2 BIIB104 Drug Overview
4.6.3 BIIB104 Mechanism of Action
4.6.4 BIIB104 Licensing/Collaboration Companies
4.6.5 BIIB104 Clinical Trials
4.7 BI 425809 Drug Details
4.7.1 BI 425809 Current Status
4.7.2 BI 425809 Drug Overview
4.7.3 BI 425809 Mechanism of Action
4.7.4 BI 425809 Licensing/Collaboration Companies
4.7.5 BI 425809 Clinical Trials
4.8 BMS-955829 Drug Details
4.8.1 BMS-955829 Current Status
4.8.2 BMS-955829 Drug Overview
4.8.3 BMS-955829 Mechanism of Action
4.8.4 BMS-955829 Licensing/Collaboration Companies
4.8.5 BMS-955829 Clinical Trials
4.9 CAD-8688 Drug Details
4.9.1 CAD-8688 Current Status
4.9.2 CAD-8688 Drug Overview
4.9.3 CAD-8688 Mechanism of Action
4.9.4 CAD-8688 Licensing/Collaboration Companies
4.9.5 CAD-8688 Clinical Trials
4.10 erteberel Drug Details
4.10.1 erteberel Current Status
4.10.2 erteberel Drug Overview
4.10.3 erteberel Mechanism of Action
4.10.4 erteberel Licensing/Collaboration Companies
4.10.5 erteberel Clinical Trials
4.11 LSN2814617 Drug Details
4.11.1 LSN2814617 Current Status
4.11.2 LSN2814617 Drug Overview
4.11.3 LSN2814617 Mechanism of Action
4.11.4 LSN2814617 Licensing/Collaboration Companies
4.11.5 LSN2814617 Clinical Trials
4.12 basmisanil Drug Details
4.12.1 basmisanil Current Status
4.12.2 basmisanil Drug Overview
4.12.3 basmisanil Mechanism of Action
4.12.4 basmisanil Licensing/Collaboration Companies
4.12.5 basmisanil Clinical Trials
4.13 Cognition disorder therapeutics Drug Details
4.13.1 Cognition disorder therapeutics Current Status
4.13.2 Cognition disorder therapeutics Drug Overview
4.13.3 Cognition disorder therapeutics Mechanism of Action
4.13.4 Cognition disorder therapeutics Licensing/Collaboration Companies
4.13.5 Cognition disorder therapeutics Clinical Trials
4.14 IPR-19 Drug Details
4.14.1 IPR-19 Current Status
4.14.2 IPR-19 Drug Overview
4.14.3 IPR-19 Mechanism of Action
4.14.4 IPR-19 Licensing/Collaboration Companies
4.14.5 IPR-19 Clinical Trials
4.15 PF-03463275 Drug Details
4.15.1 PF-03463275 Current Status
4.15.2 PF-03463275 Drug Overview
4.15.3 PF-03463275 Mechanism of Action
4.15.4 PF-03463275 Licensing/Collaboration Companies
4.15.5 PF-03463275 Clinical Trials
4.16 SKL20540 Drug Details
4.16.1 SKL20540 Current Status
4.16.2 SKL20540 Drug Overview
4.16.3 SKL20540 Mechanism of Action
4.16.4 SKL20540 Licensing/Collaboration Companies
4.16.5 SKL20540 Clinical Trials
4.17 SP-14040 Drug Details
4.17.1 SP-14040 Current Status
4.17.2 SP-14040 Drug Overview
4.17.3 SP-14040 Mechanism of Action
4.17.4 SP-14040 Licensing/Collaboration Companies
4.17.5 SP-14040 Clinical Trials
4.18 SUVN-D4010 Drug Details
4.18.1 SUVN-D4010 Current Status
4.18.2 SUVN-D4010 Drug Overview
4.18.3 SUVN-D4010 Mechanism of Action
4.18.4 SUVN-D4010 Licensing/Collaboration Companies
4.18.5 SUVN-D4010 Clinical Trials
4.19 SUVN-G3031 Drug Details
4.19.1 SUVN-G3031 Current Status
4.19.2 SUVN-G3031 Drug Overview
4.19.3 SUVN-G3031 Mechanism of Action
4.19.4 SUVN-G3031 Licensing/Collaboration Companies
4.19.5 SUVN-G3031 Clinical Trials
4.20 TAK-041 Drug Details
4.20.1 TAK-041 Current Status
4.20.2 TAK-041 Drug Overview
4.20.3 TAK-041 Mechanism of Action
4.20.4 TAK-041 Licensing/Collaboration Companies
4.20.5 TAK-041 Clinical Trials
4.21 TAK-831 Drug Details
4.21.1 TAK-831 Current Status
4.21.2 TAK-831 Drug Overview
4.21.3 TAK-831 Mechanism of Action
4.21.4 TAK-831 Licensing/Collaboration Companies
4.21.5 TAK-831 Clinical Trials
4.22 VQW-765 Drug Details
4.22.1 VQW-765 Current Status
4.22.2 VQW-765 Drug Overview
4.22.3 VQW-765 Mechanism of Action
4.22.4 VQW-765 Licensing/Collaboration Companies
4.22.5 VQW-765 Clinical Trials
5. LATEST COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA (CIAS) PIPELINE NEWS AND DEALS
6. APPENDIX
6.1 Our Databases and Reports
6.2 Research Methodolgy
1.1 List of Tables
1.2 List of Figures
2. EXECUTIVE SUMMARY
2.1 Report Scope and Research Methodology
2.2 Introduction to Cognitive Impairment Associated With Schizophrenia (CIAS) Condition
2.3 Cognitive Impairment Associated With Schizophrenia (CIAS) Pipeline Snapshot, 2020
2.4 Companies investing in Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline therapeutics
2.5 Phase wise Cognitive Impairment Associated With Schizophrenia (CIAS) Pipeline Candidates
2.6 Most Researched Mechanism of Action of Cognitive Impairment Associated With Schizophrenia (CIAS) Pipeline Products
2.7 Route of Administration of Cognitive Impairment Associated With Schizophrenia (CIAS) Pipeline Drugs
3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT
3.1 Anvyl LLC Overview, Contacts and ASD Pipeline Drugs
3.2 Astellas Pharma Inc Overview, Contacts and ASD Pipeline Drugs
3.3 AstraZeneca Plc Overview, Contacts and ASD Pipeline Drugs
3.4 Autifony Therapeutics Ltd Overview, Contacts and ASD Pipeline Drugs
3.5 Biogen Inc Overview, Contacts and ASD Pipeline Drugs
3.6 Boehringer Ingelheim International GmbH Overview, Contacts and ASD Pipeline Drugs
3.7 Bristol-Myers Squibb Co Overview, Contacts and ASD Pipeline Drugs
3.8 Cadent Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.9 Chugai Pharmaceutical Co Ltd Overview, Contacts and ASD Pipeline Drugs
3.10 Eli Lilly and Co Overview, Contacts and ASD Pipeline Drugs
3.11 INVENT Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
3.12 Iproteos SL Overview, Contacts and ASD Pipeline Drugs
3.13 Pfizer Inc Overview, Contacts and ASD Pipeline Drugs
3.14 SK Biopharmaceuticals Co Ltd Overview, Contacts and ASD Pipeline Drugs
3.15 Spherium Biomed SL Overview, Contacts and ASD Pipeline Drugs
3.16 Suven Life Sciences Ltd Overview, Contacts and ASD Pipeline Drugs
3.17 Takeda Pharmaceutical Co Ltd Overview, Contacts and ASD Pipeline Drugs
3.18 Vanda Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
4. ACTIVE PIPELINE DRUG DETAILS, 2020
4.1 AVL-3288 Drug Details
4.1.1 AVL-3288 Current Status
4.1.2 AVL-3288 Drug Overview
4.1.3 AVL-3288 Mechanism of Action
4.1.4 AVL-3288 Licensing/Collaboration Companies
4.1.5 AVL-3288 Clinical Trials
4.2 ASP4345 Drug Details
4.2.1 ASP4345 Current Status
4.2.2 ASP4345 Drug Overview
4.2.3 ASP4345 Mechanism of Action
4.2.4 ASP4345 Licensing/Collaboration Companies
4.2.5 ASP4345 Clinical Trials
4.3 ASP5736 Drug Details
4.3.1 ASP5736 Current Status
4.3.2 ASP5736 Drug Overview
4.3.3 ASP5736 Mechanism of Action
4.3.4 ASP5736 Licensing/Collaboration Companies
4.3.5 ASP5736 Clinical Trials
4.4 VU-0467154 Drug Details
4.4.1 VU-0467154 Current Status
4.4.2 VU-0467154 Drug Overview
4.4.3 VU-0467154 Mechanism of Action
4.4.4 VU-0467154 Licensing/Collaboration Companies
4.4.5 VU-0467154 Clinical Trials
4.5 AUT 00206 Drug Details
4.5.1 AUT 00206 Current Status
4.5.2 AUT 00206 Drug Overview
4.5.3 AUT 00206 Mechanism of Action
4.5.4 AUT 00206 Licensing/Collaboration Companies
4.5.5 AUT 00206 Clinical Trials
4.6 BIIB104 Drug Details
4.6.1 BIIB104 Current Status
4.6.2 BIIB104 Drug Overview
4.6.3 BIIB104 Mechanism of Action
4.6.4 BIIB104 Licensing/Collaboration Companies
4.6.5 BIIB104 Clinical Trials
4.7 BI 425809 Drug Details
4.7.1 BI 425809 Current Status
4.7.2 BI 425809 Drug Overview
4.7.3 BI 425809 Mechanism of Action
4.7.4 BI 425809 Licensing/Collaboration Companies
4.7.5 BI 425809 Clinical Trials
4.8 BMS-955829 Drug Details
4.8.1 BMS-955829 Current Status
4.8.2 BMS-955829 Drug Overview
4.8.3 BMS-955829 Mechanism of Action
4.8.4 BMS-955829 Licensing/Collaboration Companies
4.8.5 BMS-955829 Clinical Trials
4.9 CAD-8688 Drug Details
4.9.1 CAD-8688 Current Status
4.9.2 CAD-8688 Drug Overview
4.9.3 CAD-8688 Mechanism of Action
4.9.4 CAD-8688 Licensing/Collaboration Companies
4.9.5 CAD-8688 Clinical Trials
4.10 erteberel Drug Details
4.10.1 erteberel Current Status
4.10.2 erteberel Drug Overview
4.10.3 erteberel Mechanism of Action
4.10.4 erteberel Licensing/Collaboration Companies
4.10.5 erteberel Clinical Trials
4.11 LSN2814617 Drug Details
4.11.1 LSN2814617 Current Status
4.11.2 LSN2814617 Drug Overview
4.11.3 LSN2814617 Mechanism of Action
4.11.4 LSN2814617 Licensing/Collaboration Companies
4.11.5 LSN2814617 Clinical Trials
4.12 basmisanil Drug Details
4.12.1 basmisanil Current Status
4.12.2 basmisanil Drug Overview
4.12.3 basmisanil Mechanism of Action
4.12.4 basmisanil Licensing/Collaboration Companies
4.12.5 basmisanil Clinical Trials
4.13 Cognition disorder therapeutics Drug Details
4.13.1 Cognition disorder therapeutics Current Status
4.13.2 Cognition disorder therapeutics Drug Overview
4.13.3 Cognition disorder therapeutics Mechanism of Action
4.13.4 Cognition disorder therapeutics Licensing/Collaboration Companies
4.13.5 Cognition disorder therapeutics Clinical Trials
4.14 IPR-19 Drug Details
4.14.1 IPR-19 Current Status
4.14.2 IPR-19 Drug Overview
4.14.3 IPR-19 Mechanism of Action
4.14.4 IPR-19 Licensing/Collaboration Companies
4.14.5 IPR-19 Clinical Trials
4.15 PF-03463275 Drug Details
4.15.1 PF-03463275 Current Status
4.15.2 PF-03463275 Drug Overview
4.15.3 PF-03463275 Mechanism of Action
4.15.4 PF-03463275 Licensing/Collaboration Companies
4.15.5 PF-03463275 Clinical Trials
4.16 SKL20540 Drug Details
4.16.1 SKL20540 Current Status
4.16.2 SKL20540 Drug Overview
4.16.3 SKL20540 Mechanism of Action
4.16.4 SKL20540 Licensing/Collaboration Companies
4.16.5 SKL20540 Clinical Trials
4.17 SP-14040 Drug Details
4.17.1 SP-14040 Current Status
4.17.2 SP-14040 Drug Overview
4.17.3 SP-14040 Mechanism of Action
4.17.4 SP-14040 Licensing/Collaboration Companies
4.17.5 SP-14040 Clinical Trials
4.18 SUVN-D4010 Drug Details
4.18.1 SUVN-D4010 Current Status
4.18.2 SUVN-D4010 Drug Overview
4.18.3 SUVN-D4010 Mechanism of Action
4.18.4 SUVN-D4010 Licensing/Collaboration Companies
4.18.5 SUVN-D4010 Clinical Trials
4.19 SUVN-G3031 Drug Details
4.19.1 SUVN-G3031 Current Status
4.19.2 SUVN-G3031 Drug Overview
4.19.3 SUVN-G3031 Mechanism of Action
4.19.4 SUVN-G3031 Licensing/Collaboration Companies
4.19.5 SUVN-G3031 Clinical Trials
4.20 TAK-041 Drug Details
4.20.1 TAK-041 Current Status
4.20.2 TAK-041 Drug Overview
4.20.3 TAK-041 Mechanism of Action
4.20.4 TAK-041 Licensing/Collaboration Companies
4.20.5 TAK-041 Clinical Trials
4.21 TAK-831 Drug Details
4.21.1 TAK-831 Current Status
4.21.2 TAK-831 Drug Overview
4.21.3 TAK-831 Mechanism of Action
4.21.4 TAK-831 Licensing/Collaboration Companies
4.21.5 TAK-831 Clinical Trials
4.22 VQW-765 Drug Details
4.22.1 VQW-765 Current Status
4.22.2 VQW-765 Drug Overview
4.22.3 VQW-765 Mechanism of Action
4.22.4 VQW-765 Licensing/Collaboration Companies
4.22.5 VQW-765 Clinical Trials
5. LATEST COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA (CIAS) PIPELINE NEWS AND DEALS
6. APPENDIX
6.1 Our Databases and Reports
6.2 Research Methodolgy
